Higher preconception maternal and paternal vitamin B12 was tied to fewer birth defects in a Shanghai cohort of 3032 couples.
|Articles|May 1, 2005
Jaundice in a newborn: Answers to questions about a common clinical problem. First of two parts.
Yes, jaundice in newborns is prevalent and usually benign, but these babies still need ongoing clinical assessment. Part 1 reviews ways to identify and categorize hyperbilirubinemia and sets out the testing that a jaundiced infant requires.
Advertisement
Advertisement
Related to this article
CDC's 2025 NIS-Teen data show HPV vaccine coverage flat for a fourth year, with rural adolescents 12 points behind urban peers in receiving ≥1 dose.
Semaglutide cut testosterone by half in early trial data — but one patient's rapid weight loss revealed a real risk. Our experts weigh the promise of GLP-1 therapy against how fast is too fast for teens.
Which labs actually change management? Our experts debate fasting insulin versus A1c, explain why total testosterone can mislead, and share the LH-to-FSH trick that helps settle ambiguous cases.
Most patients meet PMOS in a primary care office first. Our experts map the referral threshold and argue insulin resistance — not just androgens — should drive how aggressively PCPs treat.
Ovarian ultrasound doesn't apply to teens. Our experts walk through the 2-criteria threshold for adolescents, the "at risk" category, and why untreated menstrual irregularity carries real long-term consequences.
A global Lancet consensus just renamed PCOS to PMOS. Our experts explain why the shift moves care beyond the ovaries — and what it means for how clinicians talk to patients today.
The approval is based on BRAVE-AA-PEDS, in which 42% of adolescents receiving baricitinib 4 mg achieved at least 80% scalp hair coverage at week 36 vs 5% with placebo.
Advertisement
Advertisement
Trending on Contemporary Pediatrics
1
FDA approves baricitinib for adolescents with severe alopecia areata
2
FAQ: How should pediatricians hand off teens with diabetes?
3
GLP-1 receptor agonists tied to nutritional deficiencies in children, study finds
4
FDA approves obinutuzumab to reduce relapse risk in childhood-onset idiopathic nephrotic syndrome
5